Please ensure Javascript is enabled for purposes of website accessibility

Why Tonix Pharmaceuticals Stock Is Jumping Today

By Keith Speights - Apr 19, 2021 at 11:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company struck a deal to bolster its COVID-19 pipeline.

What happened

Shares of Tonix Pharmaceuticals Holding (TNXP 2.19%) were jumping 8.1% higher as of 10:45 a.m. EDT on Monday after rising as much as 19.4% earlier in the day. The big gain came after the company announced an agreement with OyaGen to license experimental COVID-19 antiviral drug TNX-3500 (formerly known as OYA1).

So what

Investors cheered Tonix's licensing agreement because it gives the company another pipeline candidate with promising potential. In preclinical testing, TNX-3500 was found to be roughly 65 times more effective at inhibiting SARS-CoV-2 (the coronavirus that causes COVID-19) than Gilead Sciences' remdesivir.

Gloved hand between wood dominos spelling COVID-19 that have fallen down and other wood dominos that are standing up

Image source: Getty Images.

TNX-3500 has been researched for a long time. The experimental drug was studied by the National Cancer Institute back in the 1960s as a possible cancer treatment. Although it didn't prove to be effective at treating cancer, the studies from decades ago showed that the active ingredient in TNX-3500 was safe in nonhuman primates and humans with daily or weekly doses.

No financial terms were announced from Tonix's licensing deal with OyaGen. Tonix has an exclusive worldwide license for all of the technology and patents for TNX-3500 and other related compounds.

Now what

Tonix now plans to conduct additional studies evaluating TNX-3500 in treating COVID-19 in the hopes that it can proceed toward regulatory approval. In the meantime, there are a couple of other potential catalysts on the way for the biotech stock. Tonix expects to report interim results from a late-stage study of TNX-102 SL in treating fibromyalgia in the fourth quarter of this year. The company also hopes to advance experimental COVID-19 vaccine TNX-1800 into phase 1 clinical testing in the second half of 2021. 

Keith Speights doesn't own shares of any stock mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tonix Pharmaceuticals Holding Corp. Stock Quote
Tonix Pharmaceuticals Holding Corp.
$1.40 (2.19%) $0.03
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.96 (0.82%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.